Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q96IY1
UPID:
NSL1_HUMAN
Alternative names:
-
Alternative UPACC:
Q96IY1; E7ETD5; Q5SY75; Q9H2M5; Q9NRN8; Q9Y415
Background:
Kinetochore-associated protein NSL1 homolog plays a crucial role in mitosis, being a part of the MIS12 complex. This complex is essential for proper chromosome alignment, segregation, and kinetochore formation, processes fundamental for cell division.
Therapeutic significance:
Understanding the role of Kinetochore-associated protein NSL1 homolog could open doors to potential therapeutic strategies.